<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706845</url>
  </required_header>
  <id_info>
    <org_study_id>AL Patient Burden 01</org_study_id>
    <nct_id>NCT04706845</nct_id>
  </id_info>
  <brief_title>Understanding the Burden of ACC Through the Eyes of Patients</brief_title>
  <official_title>Understanding the Burden of ACC Through the Eyes of Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ayala Pharmaceuticals, Inc,</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adenoid Cystic Carcinoma Research Foundation (ACCRF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Engage Health Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ayala Pharmaceuticals, Inc,</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals&#xD;
      affected by ACC who may know the results of molecular profiling of their tumor.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        -  To identify the specific burdens faced by patients with ACC&#xD;
&#xD;
        -  To compare/contrast the burdens faced by patients with ACC at different disease stages&#xD;
           (no evident disease, metastatic disease/watchful waiting, progressive disease)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals&#xD;
      affected by ACC who may know the results of molecular profiling of their tumor.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        -  To identify the specific burdens faced by patients with ACC&#xD;
&#xD;
        -  To compare/contrast the burdens faced by patients with ACC at different disease stages&#xD;
           (no evident disease, metastatic disease/watchful waiting, progressive disease)&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess QoL implication in patients living with ACC (Adenoid Cystic Carcinoma)&#xD;
&#xD;
        -  To compare the burdens and QoL impacts in people living with ACC, with their tumors&#xD;
           bearing Notch mutations or Notch Wild Type due to:&#xD;
&#xD;
             -  Rate of disease progression&#xD;
&#xD;
             -  Location of Metastases&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Key burdens related to the disease or treatments</measure>
    <time_frame>Q4-2021</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Life impacts of those burdens for patient/family</measure>
    <time_frame>Q4-2021</time_frame>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Adenoid Cystic Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>No evident disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Metastatic Disease; Watchful Waiting: Tumors bearing NOTCH Mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Metastatic Disease; Watchful Waiting: Tumors bearing Notch Wild Type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Progressive Disease: Tumors bearing NOTCH Mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <description>Progressive Disease: Tumors bearing Notch Wild Type</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Within the United States or Israel, patients who have been diagnosed with Adenoid Cystic&#xD;
        Carcinoma (ACC)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must be a person diagnosed with ACC who is 18 years or older&#xD;
&#xD;
          2. For patients with metastatic disease; watchful waiting or progressive disease,&#xD;
             participants must know the results of molecular profiling of their tumor&#xD;
&#xD;
          3. Histologically-confirmed diagnosis of ACC with written proof of disease and molecular&#xD;
             profile of tumor provided. This can be a note showing genetic diagnosis from a&#xD;
             relevant testing laboratory, physician consult notes, a medical record of diagnosis,&#xD;
             or any other single piece of documentation that connects your name/the patient's name&#xD;
             with ACC.&#xD;
&#xD;
          4. Able to read, write and understand English, Hebrew, Arabic, or Russian&#xD;
&#xD;
          5. Able to grant informed consent&#xD;
&#xD;
          6. Willing to participate in a 45-to-60-minute telephone interview, including follow up&#xD;
             questions (if necessary)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Inability to meet any of the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patti Engel</last_name>
    <phone>(651)994-0510</phone>
    <email>pengel@engagehealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Austin Letcher</last_name>
    <phone>(651)994-0510</phone>
    <email>aletcher@engagehealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Engage Health</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Engel</last_name>
      <phone>651-994-0510</phone>
      <email>pengel@engagehealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Austin Letcher</last_name>
      <phone>(651)994-0510</phone>
      <email>aletcher@engagehealth.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

